Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

The potential of gene transfer into primary B-CLL cells using recombinant virus vectors.

Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M.

Leuk Lymphoma. 2004 May;45(5):897-904. Review.

PMID:
15291346
2.

Viral-mediated gene transfer for cancer treatment.

Wilson DR.

Curr Pharm Biotechnol. 2002 Jun;3(2):151-64. Review.

PMID:
12022258
3.

Gene therapy and active immune therapy of hematologic malignancies.

Wierda WG, Kipps TJ.

Best Pract Res Clin Haematol. 2007 Sep;20(3):557-68. Review.

PMID:
17707840
4.

Amplicons as vaccine vectors.

Santos K, Duke CM, Dewhurst S.

Curr Gene Ther. 2006 Jun;6(3):383-92. Review.

PMID:
16787189
5.

Improvements in gene therapy: averting the immune response to adenoviral vectors.

Ritter T, Lehmann M, Volk HD.

BioDrugs. 2002;16(1):3-10. Review.

PMID:
11908997
6.

CD154 gene therapy for human B-cell malignancies.

Messmer D, Kipps TJ.

Ann N Y Acad Sci. 2005 Dec;1062:51-60. Review.

PMID:
16461788
7.

Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors.

Dalba C, Klatzmann D, Logg CR, Kasahara N.

Curr Gene Ther. 2005 Dec;5(6):655-67. Review.

PMID:
16457654
8.
9.

Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors.

Mazda O.

Curr Gene Ther. 2002 Sep;2(3):379-92. Review.

PMID:
12189722
10.

Vaccine- and immune-based therapy in chronic lymphocytic leukemia.

Le Dieu R, Gribben J.

Semin Oncol. 2006 Apr;33(2):220-9. Review.

PMID:
16616069
11.

Viral vectors for gene therapy.

Robbins PD, Ghivizzani SC.

Pharmacol Ther. 1998 Oct;80(1):35-47. Review.

PMID:
9804053
12.

Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.

Delecluse HJ, Feederle R, Behrends U, Mautner J.

Semin Cancer Biol. 2008 Dec;18(6):409-15. doi: 10.1016/j.semcancer.2008.09.001. Epub 2008 Sep 30. Review.

PMID:
18938248
13.

Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.

Tabarkiewicz J, Giannopoulos K.

Transplant Proc. 2010 Oct;42(8):3293-6. doi: 10.1016/j.transproceed.2010.07.022. Review.

PMID:
20970674
14.

Cancer gene therapy using adeno-associated virus vectors.

Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, Cho ES, Chang SI, Moon SK, Kang BS, Kim YJ, Cho SH.

Front Biosci. 2008 Jan 1;13:2653-9. Review.

PMID:
17981740
15.

Viral vectors for gene transfer: a review of their use in the treatment of human diseases.

Walther W, Stein U.

Drugs. 2000 Aug;60(2):249-71. Review.

PMID:
10983732
16.

CD40 ligand in CLL pathogenesis and therapy.

Schattner EJ.

Leuk Lymphoma. 2000 May;37(5-6):461-72. Review.

PMID:
11042507
17.

Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus.

Oehmig A, Fraefel C, Breakefield XO, Ackermann M.

Curr Gene Ther. 2004 Dec;4(4):385-408. Review.

PMID:
15578989
18.

Receptor targeting of adeno-associated virus vectors.

B√ľning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M.

Gene Ther. 2003 Jul;10(14):1142-51. Review.

PMID:
12833123
19.

CD40 activation: potential for specific immunotherapy in B-CLL.

von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG.

Ann Oncol. 2004 Jun;15(6):853-7. Review.

PMID:
15151939
20.

Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.

Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM.

Leuk Lymphoma. 2012 Apr;53(4):537-49. doi: 10.3109/10428194.2011.610014. Epub 2011 Sep 23. Review.

PMID:
21812539

Supplemental Content

Support Center